anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Sertraline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Sertraline hydrochloride tablets are not approved for the treatment of major depressive disorder in pediatric patients. (See WARNINGS:Clinical Worsening and Suicide Risk, PRECAUTIONS:Information for Patients, and PRECAUTIONS:Pediatric Use).

  
Please review the manufacturer's complete drug information available from the FDA at www.fda.gov   
Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf71d1b9-5ebb-429f-a07f-a87cd168250f
PURPOSE:The titled composition dispersible uniformly in a bathtub, raising effect of bathing agent, keeping the skin clean by decomposing action of enzyme on effect matter, containing a foamable base consisting of a bicarbonate or a carbonate and an acidic phosphate or phrophosphate and an enzyme. CONSTITUTION:A composition containing a foamable base consisting of a bicarbonate or a carbonate and a phosphate or acidic pyrophosphate, and an enzyme. Sodium bicarbonate, potassium carbonate, etc. may be cited as the bicarbonate or carbonate, and sodium primary phosphate, potassium acidic pyrophosphate, etc. as the phosphate or the acidic pyrophosphate. A proteolytic enzyme is preferable as the enzyme. The composition has 80-40wt%, preferably 70-50wt% foamable base, a ratio of the bicarbonate or carbonate to the phosphate or pyrophosphate is preferably an equimolar ratio - an excess amount of the former. The amount of the enzyme is preferably >=0.1wt%.
This has occurred in approximately 4% of patients treated with mitomycin. Cellulitis at the injection site has been reported and is occasionally severe. Stomatitis and alopecia also occur frequently. Rashes are rarely reported. The most important dermatological problem with this drug, however, is the necrosis and consequent sloughing of tissue which results if the drug is extravasated during injection.   
  
Extravasation may occur with or without an accompanying stinging or burning sensation and even if there is adequate blood return when the injection needle is aspirated. There have been reports of delayed erythema and/or ulceration occurring either at or distant from the injection site, weeks to months after mitomycin, even when no obvious evidence of extravasation was observed during administration. Skin grafting has been required in some of the cases. Elderly patients may be more susceptible than younger patients to injection site reactions   
(see PRECAUTIONS: Geriatric Use).
This invention provides novel methods of inhibiting one or more symptoms of atherosclerosis. Also provided are assays for compounds that will inhibit the progression and/or ameliorate one or more symptoms of atherosclerosis. The methods and assays are based, in part, on the discovery that oxidized LDL or components thereof induce strong upregulation of MAP kinase phosphatase-1 which, in turn, is associated with an "inflammatory response" characteristic of atherosclerotic plaque formation. Inhibition of MKP-1 inhibits one or more symptoms of this response, e.g. monocyte adhesion, monocyte chemotaxis, differentiation into macrophages,etc. Inhibition of MKP-1 thus provides an effective method of inhibiting symptoms of atherosclerosis.
Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the automated abdominal binder combined with placebo pill t.i.d The automated abdominal binder will be placed during the morning orthostatic trial on the active/sham binder study day. The binder will inflate automatically (\~40 mmHg) every time the participant stands up throughout the study day.
High-risk patients followed an evidence-based multimodal prehabilitation program for five weeks, incorporating modalities tailored to address their impairments. Patients performed physical exercise training and/or received dietary counseling for five weeks, provided by a trained physiotherapist and dietitian (both \>15 years experience).
The invention provides a traditional Chinese medicine for treating lumbagos. The traditional Chinese medicine comprises Chinese magnoliavine fruit, Himalayan teasel roots, incised notopterygium rhizomes, white peony roots, prepared fleeceflower roots, south dodder seeds, yerbadetajo herb, cuneate lespedeza herb with root, ginseng, piper wallichii (Miq.) Hand.-Mazz. var hupehense (DC.) Hand.-mazz., flatstem milkvetch seeds, glutinous rice and pig bones. The invention further provides a preparation method of the traditional Chinese medicine for treating the lumbagos. The traditional Chinese medicine has the advantages that based on the fact that the Himalayan teasel roots are capable of well treating waist and back pain and acratia of feet and knees, the south dodder seeds are capable of treating soreness and weakness of waist and knees, spleen-kidney deficiency and diarrhoea effectively and the flatstem milkvetch seeds are mainly used for treating waist and knee pain, the traditional Chinese medicine added with the Chinese magnoliavine fruit, the incised notopterygium rhizomes, the white peony roots, the prepared fleeceflower roots, the yerbadetajo herb, the cuneate lespedeza herb with root, the ginseng and the piper wallichii (Miq.) Hand.-Mazz. var hupehense (DC.) Hand.-mazz. is capable of treating the lumbagos effectively and nourishing the liver and kidney, has good effect when being used for treating epersalgia and asthenic disease and is free from any toxic and side effects; additionally, the preparation method has the advantage that a patient can absorb decoction effectively after eating the glutinous rice containing the decoction.
Since the identification of the TTMV::RARA fusion in pediatric cases resembling acute promyelocytic leukemia (APL) by Astolfi et al. in 2021, several similar cases have been reported worldwide. In this report, we present a case of relapsed APL in an adolescent patient, who exhibited the TTMV::RARA fusion gene. This patient exhibited extensive central nervous system involvement and experienced bone marrow necrosis during disease recurrence. Despite achieving complete remission after re-induction chemotherapy, the patient experienced a rapid second relapse, highlighting the extremely aggressive nature of this subtype. These clinical manifestations contribute to the growing recognition of this rare disease.
Depression is a common and potentially serious complication of Parkinson's disease (PD). Studies show that approximately 40 percent of PD patients are depressed. There is evidence that these patients have deficits in neuropsychological function relative to non-depressed PD patients. Despite the widespread toll on emotional health posed by PD, few studies have undertaken a comprehensive examination of the neural underpinnings of Parkinsonian depression. In this project, we will compare depressed versus non-depressed Parkinson patients to a sample of demographically-matched healthy controls using neuropsychological assessment and magnetic resonance imaging (MRI). To investigate possible effects of anti-Parkinsonian medication on mood, cognitive function, and neural response, PD patients will be tested both off and on Parkinsonian medications.
Following randomization, the control group will receive usual preoperative care consisting of two to four multidisciplinary visits over six months. During this time, patients will be provided with exercise counseling through the team kinesiologist. They will complete a behavior modification program called Craving ChangeTM and must achieve usual goals of lifestyle and dietary modification, along with modest weight loss of approximately 5%, in order to be scheduled for surgery. Patients will also complete a liquid diet consisting of 900 calories per day for two weeks prior to their procedure in order to reduce intra-abdominal obesity and facilitate the procedure.
Narcotic analgesics cross the placental barrier. The closer to delivery and the larger the dose used, the greater the possibility of respiratory depression in the newborn. Narcotic analgesics should be avoided during labor if delivery of a premature infant is anticipated. If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for signs of respiratory depression. Resuscitation may be required (see ). OVERDOSAGE

Limited data suggest that use of promethazine hydrochloride during labor and delivery does not have an appreciable effect on the duration of labor or delivery and does not increase the risk of need for intervention in the newborn.

The effect of promethazine and/or codeine on the later growth and development of the newborn is unknown.
Objective. Methods of detecting apnea based on acoustic features can be prone to misdiagnosed and missed diagnoses due to the influence of noise. The aim of this paper is to improve the performance of apnea detection algorithms in the Post Anesthesia Care Unit (PACU) using a denoising method that processes tracheal sounds without the need for separate background noise.Approach. Tracheal sound data from laboratory subjects was collected using a microphone. Record a segment of clinical background noise and clean tracheal sound data to synthesize the noisy tracheal sound data according to a specified signal-to-noise ratio. Extract the frequency-domain features of the tracheal sounds using the Short Time Fourier Transform (STFT) and input the Cascaded Redundant Convolutional Encoder-Decoder network (CR-CED) network for training. Patients' tracheal sound data collected in the PACU were then fed into the CR-CED network as test data and inversely transformed by STFT to obtain denoised tracheal sounds. The apnea detection algorithm was used to detect the tracheal sound after denoising.Results. Apnea events were correctly detected 207 times and normal respiratory events 11,305 times using tracheal sounds denoised by the CR-CED network. The sensitivity and specificity of apnea detection were 88% and 98.6%, respectively.Significance. The apnea detection results of tracheal sounds after CR-CED network denoising in the PACU are accurate and reliable. Tracheal sound can be denoised using this approach without separate background noise. It effectively improves the applicability of the tracheal sound denoising method in the medical environment while ensuring its correctness.
CONTEXT.—: Intraductal papillary neoplasm of the bile duct (IPNB) is classified into types 1 and 2 based on criteria proposed in 2019. Recent studies investigated the clinicopathologic and molecular features of IPNB, which contributed to a more detailed understanding of this undercharacterized neoplasm.
OBJECTIVE.—: To summarize driver gene mutations, radiologic tumor evolution, and a potentially unique pattern of tumor progression in IPNB.
DATA SOURCES.—: Data were derived from a literature review and personal clinical and research experiences.
CONCLUSIONS.—: In contrast to de novo cholangiocarcinoma, type 1 IPNB often has mutations in APC, CTNNB1, STK11, and GNAS. These molecular features are shared with intraductal papillary mucinous neoplasm of the pancreas; however, the frequencies of individual gene abnormalities differ between these 2 neoplasms. A radiologic review of sequential images suggested that type 1 IPNB is a slow-growing neoplasm, with an ∼1-cm increase in size every 2 to 3 years, and remains in a noninvasive state for many years. A similar papillary neoplasm may develop in the biliary tree years after the complete surgical resection of IPNB. The second neoplasm has the same genetic abnormalities as the first neoplasm, indicating intrabiliary implantation rather than multifocal lesions. In contrast to type 1 IPNB, most cases of type 2 IPNB have invasive malignancy at the initial presentation. Type 2 IPNB shares many clinicopathologic and molecular features with de novo cholangiocarcinoma, questioning the distinctness of this tumor entity. The molecular mechanisms underlying malignant transformation in IPNB warrant further study.
In this study, a relaxation program will be applied to mothers who have a child followed up with a cancer diagnosis. The relaxation program will include progressive muscle relaxation exercises and videos for relaxation. Initial applications will be implemented with caregivers. The relaxation program is planned to last 6 weeks. The program is planned to last 8 weeks in total, with pre-test and post-test applications. Caregivers will then be asked to perform the treatments each week. Coping with Stress and State-Trait Anxiety Scale will be used at the beginning and end of the program.
This is a single-arm, open-label study that will investigate the efficacy and safety profile of pomalidomide in patients with genetically-documented Hereditary Hemorrhagic Telangiectasia (defined by characteristic mutations in Eng, Alk-1 or Smad-4) or idiopathic vascular ectasia with no documented mutations, leading to refractory bleeding of the small bowel. This study will be limited to patients with documented bleeding from the small bowel, including the duodenum, jejunum or ileum. Eligible patients will be dependent on transfusion or intravenous iron therapy (requiring at least 4 units of blood transfusion or 4 iron infusions over the preceding 4 months) and will have endoscopically-confirmed areas of vascular ecstasia. Therapy for all eligible patients will be initiated with a 1 mg daily dose of pomalidomide. The principal investigator will determine whether intrapatient dose escalation is indicated based on the response of the patient's bleeding during the first 30 days of therapy. If dose escalation is indicated, pomalidomide will be increased at the investigator's discretion to a maximal dose of 5 mg/day. Cessation of GI bleeding will be defined as maintenance of stable hemoglobin without blood transfusion or intravenous iron therapy over a 4 week period. Once GI bleeding has ceased, patients will be maintained at a stable pomalidomide dose for an additional 4 months, and the dose then tapered by 1 mg per month, or until bleeding recurs. Patients will be followed for a total of six months post-therapy to determine whether the response is maintained.
Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.
Participants will be ultra-endurance athletes competing in Racing the Planet's 250 mile/7 day 4 Desert events in 2014 (Jordan, Gobi, Madagascar, and Atacama. A convenience sample will be used, with full consent signed before inclusion into the study, with participants being informed that study inclusion is entirely optional and will not affect medical care. Randomization will be conducted for each participant, a coin will be flipped to determine which foot is to be taped, heads - right foot, and tails, left foot. The non-taped foot will be used as a control. The runner's normal sock/shoe system will be used to reflect natural wilderness conditions. Participants will have demographic data collected prior to the race, including age, gender, country of origin, number of marathons run prior, pack weight, and sock type. The study endpoint occurs when a hot spot or blister develops on either the treated or untreated foot. Runners will be instructed to treat suspected blisters or hot spots as they normally would, and to inform the study administrators the same day for visual inspection and final questionnaire to determine if they develop blisters or hot spots, whether they applied or re-applied tape themselves, removed tape, and the reasons for these actions.

Participants will have tape applied to area(s) prone to blister on 1 foot, if no blister history, 1 area will be randomly assigned. The tape will be left on the selected foot until a blister or hot spot develops on either foot or the end of the race, whichever comes first. At that point, the study is over and the participant can continue or stop taping at their choice. If participants are prone to blisters or hot spots in particular areas, 1" paper tape applied to that site on trial foot. However, if the participant has no previous blister or hot spot experience, a site will be randomly assigned by picking a piece of paper out of a bag with the site written on a piece of paper (heel, toe, instep, head of 5th metatarsal). Therefore, a single participant can have more than 1 site on an individual foot.
INTRODUCTION AND HYPOTHESES: The International Continence Society recommends the International Consultation on Incontinence Questionnaire-Bladder Diary (ICIQ-BD) for the assessment, management, and monitoring of lower urinary tract symptoms (LUTS). Translation, cross-cultural adaptation and validation will establish a valid and reliable tool for Brazilian women with LUTS.
METHODS: A cross-sectional study involving 101 women was carried out at the Urogynecology Outpatient Clinic in Belo Horizonte, Brazil, between August 2020 and April 2022. The process of cross-cultural adaptation and validation was executed following the ICIQ Group's protocol. Reviewed by an expert committee, the first pre-test was followed by subsequent adaptations, resulting in a second adapted version that underwent expert revisions. A second pretest was conducted, followed by cross-cultural adaptation and construct validation. Finally, the International Consultation on Incontinence Questionnaire-Bladder Diary-Brazilian Portuguese Version (ICIQ-BD-Br) underwent a validation process.
RESULTS: Construct validity (IVC >0.78) and internal consistency were satisfactory (α-Cronbach coefficient 0.87-0.94). The following adjustments were made: a specific field was created to document sleep and wake times, and a printed score ranging from 0 to 4 was included in the bladder sensation column. Test-retest reliability ranged from fair to excellent for all analyzed items (Spearman correlation: 0.64-0.95). Criterion validity analysis indicated slight agreement for one of the four symptoms analyzed (nocturia k=0.32). The final version was approved by the ICIQ Group.
CONCLUSIONS: The ICIQ-BD-Br has been adapted for use in Brazilian Portuguese and has exhibited robust construct validity and reliability for Brazilian women with LUTS.
Mayaro virus (MAYV), a mosquito-borne alphavirus, is considered an emerging threat to public health with epidemic potential. Phylogenetic studies show the existence of three MAYV genotypes. In this study, we provide a preliminary analysis of the pathogenesis of all three MAYV genotypes in cynomolgus macaques (Macaca facicularis, Mauritian origin). Significant MAYV-specific RNAemia and viremia were detected during acute infection in animals challenged intravenously with the three MAYV genotypes, and strong neutralizing antibody responses were observed. MAYV RNA was detected at high levels in lymphoid tissues, joint muscle and synovia over 1 month after infection, suggesting that this model could serve as a promising tool in studying MAYV-induced chronic arthralgia, which can persist for years. Significant leucopenia was observed across all MAYV genotypes, peaking with RNAemia. Notable differences in the severity of acute RNAemia and composition of cytokine responses were observed among the three MAYV genotypes. Our model showed no outward signs of clinical disease, but several major endpoints for future MAYV pathology and intervention studies are described. Disruptions to normal blood cell counts and cytokine responses were markedly distinct from those observed in macaque models of CHIKV infection, underlining the importance of developing non-human primate models specific to MAYV infection.
PURPOSE: A manufacturing method of heterocyclic compounds is provided to shorten operation time and to simplify the operation process and to manufacture the compounds at high purity and high yield. CONSTITUTION: A manufacturing method of heterocyclic compounds of chemical formula 1 comprises a step of reacting a compound of chemical formula 2 with active materials. The active material is inorganic base or pyridine. The inorganic base is hydroxysalt of alkali metal. The hydroxysalt of the alkali metal is NaOH, lithium hydroxide or potassium hydroxide. 1-10 equivalent of the inorganic base is used based on 1 equivalent of the compound of chemical formula 2. 1-30 ml of the pyridine is used based on 1g of the compound of the chemical formula 2. 0.5-200 equivalent of pyridine is used based on 1 equivalent of inorganic base. The reaction temperature is 0-100 deg. Celsius. The compound of the chemical formula 2 is manufactured by reacting a compound of chemical formula 3 with alkylchloroformate.
The invention discloses a paclitaxel submicron emulsion with a lipid compound as an intermediate carrier. With the paclitaxel lipid compound as the intermediate carrier, the paclitaxel is solved in oil phase, and water phase, emulsifier and auxiliary emulsifier are added. Emulsion droplet grain diameter is less than 600nm; the proportion of the oil phase and the water phase is 5 to 95 to 35 to 65; and the drug loading quantity is 0.25mg/ml to 5mg/ml if counted according to the paclitaxel. The prepared submicron emulsion has high drug loading quantity, is resistant for autoclaving and has stable quality after long time storage. The submicron emulsion can be made into intravenous drip transfusion directly, as well as into dry emulsion by a freeze drying technology, and when being used, the submicron emulsion is added with physiological saline or glucose to be diluted into intravenous drip.. The submicron emulsion uses nontoxic refined plant oil as the oil phase and phospholipid as the emulsifier, drug is coated in the oil phase, and thereby the submicron emulsion reduces the irritation and the adverse reaction of the paclitaxel preparation and has good safety.